Impact of concurrent CMV colitis on clinical outcomes in immune checkpoint inhibitor‒induced colitis

Authors:

Abstract
Background and aims Immune checkpoint inhibitors (ICI) frequently trigger ICI-colitis, commonly leading to ICI discontinuation. With increasing ICI use, ICI-colitis is an emerging clinical challenge. Cytomegalovirus (CMV) infection is known to occur in ICI-colitis, but its prevalence, risk factors, and impact are poorly defined. This study aimed to characterise colonic CMV infection in ICI-colitis using robust definitions and a CMV-negative comparator group. MethodsWe retrospectively analysed consecutive ICI- treated patients with endoscopically and/or histologically confirmed ICI-colitis at two UK hospitals between 2015 and 2024. Clinical, endoscopic (Mayo Endoscopic Score, MES), treatment and oncologic outcome data were collected. CMV was identified by immunohistochemistry (IHC) on colonic biopsies. CMV-positive cases were compared with CMV-negative controls using chi- squared, Mann-Whitney U and multivariable regression analyses. ResultsAmong 249 ICI-colitis patients, CMV- colitis was detected in 21 (8.4%). CMV-positive patients were more likely to receive dual ICI therapy, have bloody stool (OR 2.7, p=0.038) and have higher endoscopic severity (MES 2–3; OR 4.1, p<0.01), despite similar diarrhoea grades. Prior infliximab exposure was strongly associated with CMV colitis (OR 5.2, p=0.002). CMV-positive cases more frequently required escalation to advanced therapy (80% vs 41.5%; OR 5.6, p=0.002), remaining significant after adjustment for endoscopic severity (p=0.049). Colectomy rates were higher albeit low overall. Antiviral therapy did not significantly affect corticosteroid duration or recurrence, and CMV status did not influence overall or progression-free survival. ConclusionConcurrent CMV colitis occurs in a notable subset of ICI-colitis patients and may worsen disease severity, highlighting the importance of endoscopic biopsy, especially in steroid-refractory cases.